NCCN Guidelines Insights: Bone Cancer, Version 2.2017

• DOI: 10.6004/jnccn.2017.0017
• Publication Date: 2017-05-26T11:18:59Z
• Authors: J. Sybil Biermann; Warren Chow; Damon R. Reed; David Lucas; Douglas R. Adkins; Mark Agulnik; Robert S. Benjamin; Brian Brigman; G. Thomas Budd; William T. Curry; Aarati Didwania; Nicola Fabbri; Francis J. Hornicek; Joseph B. Kuechle; Dieter Lindskog; Joel Mayerson; Sean V. McGarry; Lynn Million; Carol D. Morris; Sujana Movva; Richard J. O'Donnell; R. Lor Randall; Peter Rose; Victor M. Santana; Robert L. Satcher; Herbert Schwartz; Herrick J. Siegel; Katherine Thornton; Victor Villalobos; Mary Anne Bergman; Jillian L. Scavone
• Keywords: Clinical Trials as Topic; Biopsy; Incidence; Antineoplastic Agents; Bone Neoplasms; Chemoradiotherapy, Adjuvant; Sarcoma, Ewing; Medical Oncology; Prognosis; Magnetic Resonance Imaging; Amputation, Surgical; 3. Good health; Survival Rate; 03 medical and health sciences; 0302 clinical medicine; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Positron Emission Tomography Computed Tomography; Antineoplastic Combined Chemotherapy Protocols; Practice Guidelines as Topic; Humans; Neoplasm Recurrence, Local; Neoplasm Staging

The NCCN Guidelines for Bone Cancer provide interdisciplinary recommendations for treating chordoma, chondrosarcoma, giant cell tumor of bone, Ewing sarcoma, and osteosarcoma. These NCCN Guidelines Insights summarize the NCCN Bone Cancer Panel's guideline recommendations for treating Ewing sarcoma. The data underlying these treatment recommendations are also discussed.